Prognostic factors influencing implant survival and marginal bone loss in patients with osteoporosis or osteopenia medication
10.5125/jkaoms.2025.51.1.17
- Author:
Sun-A LEE
1
;
Yang-Jin YI
;
Seunghyun WON
;
Na-Hee CHANG
;
Jong-Hee KIM
Author Information
1. Department of Prosthodontics, Section of Dentistry, Seoul National University Bundang Hospital, Seongnam, Korea
- Publication Type:ORIGINAL ARTICLE
- From:Journal of the Korean Association of Oral and Maxillofacial Surgeons
2025;51(1):17-25
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objectives:To evaluate the factors that influence the survival of dental implants and marginal bone loss (MBL) in patients taking osteoporosis or osteopenia medication.
Materials and Methods:This study included patients who underwent dental implant treatment after taking medication for osteoporosis or osteopenia. Electronic medical records were used to collect data of patient age, sex, age at osteoporosis or osteopenia diagnosis, types of medications, age at medication initiation, duration of medication before implant surgery, whether the medication was paused before surgery, paused duration of medication, implant survival status, and MBL before and after prosthetic treatment. Firth’s logistic regression was used to analyze the relationships between each variable and implant survival as well as between MBL before and after prosthetic treatment.
Results:Of the 267 patients, 111 with 209 implants were included in the study. The mean observation period was 57.9 months. The survival rate was 92.8% at the patient level and 96.2% at the implant level. No significant associations were found between implant survival and any of the variablesexamined. MBL before prosthetic treatment was significantly associated with use of receptor activator of nuclear factor-κB ligand (RANKL) inhibitors(P=0.032) and bone formation stimulators (P=0.022). Comparing the concurrent and single use of bisphosphonates and RANKL inhibitors, only the use of RANKL inhibitors alone was significantly associated with MBL before prosthetic treatment (P=0.039). MBL after prosthetic treatment was significantly associated with injection method among the routes of drug administration (P=0.011).
Conclusion:The implant survival rate in patients undergoing medical treatment for osteoporosis or osteopenia was comparable to the general implant survival rate. MBL before prosthetic treatment was associated with type of anti-osteoporotic medication, whereas MBL after prosthetic treatment was correlated with drug administration route. Further studies with larger sample sizes are required.
